Literature DB >> 12825823

Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature.

Peter Widdess-Walsh1, Jinny O Tavee, Stephan Schuele, Glen H Stevens.   

Abstract

Paraneoplastic cerebellar degeneration (PCD) is a debilitating neuro-degenerative disease associated with antibodies directed against the purkinje cells of the cerebellum. Treatment using chemotherapy or other treatment of the primary tumor to various immunologically directed therapies has been attempted but outcomes have been poor. We discuss a patient with ovarian carcinoma and PCD seen in our institution who showed a marked beneficial response to intravenous immunoglobulin (IVIG) and methylprednisolone. A Medline search from 1966-2002 produced fifteen cases of PCD confirmed by antibody testing that were treated with IVIG, either alone, or with a combination of other therapies. The clinical characteristics and treatment responses of these patients are analyzed in this review. Most patients that were treated with IVIG and had what was defined as a good response were treated within one month of symptoms. Patients treated between one month and three months often had stable disease and patients treated after three months of symptoms usually had a poor outcome. Early treatment with sufficiently high doses of IVIG seems to provide a better chance of treatment success. The additional benefit of early high dose intravenous methylprednisolone is unclear. Due to the devastating nature of the disease, a trial of IVIG and steroids is warranted as early as possible in a dose of 2g/kg to any patient with a clinical picture of PCD and positive antibodies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12825823     DOI: 10.1023/a:1023931501503

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  8 in total

1.  Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration.

Authors:  M L Albert; L M Austin; R B Darnell
Journal:  Ann Neurol       Date:  2000-01       Impact factor: 10.422

2.  Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies.

Authors:  M Uchuya; F Graus; F Vega; R Reñé; J Y Delattre
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-04       Impact factor: 10.154

3.  Reversal of subacute paraneoplastic cerebellar syndrome with intravenous immunoglobulin.

Authors:  C E Counsell; M McLeod; R Grant
Journal:  Neurology       Date:  1994-06       Impact factor: 9.910

4.  Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders.

Authors:  F Blaes; M Strittmatter; S Merkelbach; V Jost; M Klotz; K Schimrigk; G F Hamann
Journal:  J Neurol       Date:  1999-04       Impact factor: 4.849

5.  Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies.

Authors:  I Rojas; F Graus; F Keime-Guibert; R Reñé; J Y Delattre; J M Ramón; J Dalmau; J B Posner
Journal:  Neurology       Date:  2000-09-12       Impact factor: 9.910

6.  Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone.

Authors:  F Keime-Guibert; F Graus; A Fleury; R René; J Honnorat; P Broet; J Y Delattre
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

7.  Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report.

Authors:  Y B David; E Warner; M Levitan; D M Sutton; M G Malkin; J O Dalmau
Journal:  Cancer       Date:  1996-11-15       Impact factor: 6.860

8.  Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies.

Authors:  F Graus; F Vega; J Y Delattre; I Bonaventura; R Reñé; D Arbaiza; E Tolosa
Journal:  Neurology       Date:  1992-03       Impact factor: 9.910

  8 in total
  40 in total

1.  Long-term efficiency of intravenously administered immunoglobulin in anti-Yo syndrome with paraneoplastic cerebellar degeneration.

Authors:  J Schessl; M Schuberth; P Reilich; P Schneiderat; N Strigl-Pill; M C Walter; B Schlotter-Weigel; B Schoser
Journal:  J Neurol       Date:  2010-12-21       Impact factor: 4.849

2.  Progress in the management of paraneoplastic neurological disorders.

Authors:  Hamid Sadeghian; Steven Vernino
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

3.  Intravenous immunoglobulins in paraneoplastic brainstem encephalitis with anti-Ri antibodies.

Authors:  Arnaud Fumal; Jerome Jobe; Jean-Louis Pepin; Valerie Delvaux; Jean-Marc Senterre; Sandrine Bonaventure; Alain Maertens de Noordhout
Journal:  J Neurol       Date:  2006-09-27       Impact factor: 4.849

Review 4.  Paraneoplastic syndromes of the CNS.

Authors:  Josep Dalmau; Myrna R Rosenfeld
Journal:  Lancet Neurol       Date:  2008-04       Impact factor: 44.182

5.  Update on paraneoplastic neurologic disorders.

Authors:  Myrna R Rosenfeld; Josep Dalmau
Journal:  Oncologist       Date:  2010-05-17

6.  Strategies in detection of the primary tumour in anti-Yo associated paraneoplastic cerebellar degeneration.

Authors:  Markus Frings; Gerald Antoch; Philipp Knorn; Lutz Freudenberg; Ulrich Bier; Dagmar Timmann; Matthias Maschke
Journal:  J Neurol       Date:  2005-02       Impact factor: 4.849

7.  The role of breast MRI in the investigation of anti-Yo positive paraneoplastic cerebellar degeneration.

Authors:  Raquel Real; Ana Oliveira; Goreti Nadais; Joana Loureiro; Maria Carolina Garrett
Journal:  BMJ Case Rep       Date:  2012-03-27

Review 8.  Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration associated with cognitive affective syndrome in a patient with breast cancer: a case report and literature review.

Authors:  M Le May; S Dent
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

9.  Paraneoplastic cerebellar degeneration as a marker of endometrial cancer recurrence.

Authors:  Geoffrey Lie; Thomas Morley; Muhammad Chowdhury
Journal:  BMJ Case Rep       Date:  2016-05-18

Review 10.  Paraneoplastic movement disorders.

Authors:  Shyamal H Mehta; John C Morgan; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2009-07       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.